Quarterly report pursuant to Section 13 or 15(d)

Summary of the Net Purchase Price and Allocation to the Acquired Assets (Detail)

v3.20.2
Summary of the Net Purchase Price and Allocation to the Acquired Assets (Detail) - ProstaGene, LLC - USD ($)
3 Months Ended
Aug. 31, 2020
May 31, 2020
Business Acquisition, Contingent Consideration [Line Items]    
CytoDyn Inc. equity $ 11,558,000  
Acquisition expenses 741,000  
Release of deferred tax asset 2,827,000  
Total cost of acquisition 15,126,000  
Intangible assets 15,126,000 $ 15,126,000
Other 0  
Allocation of acquisition costs $ 15,126,000